Coronavirus Update: Coalition Aims To Overcome 'Disjointed' COVID-19 Trials, Gilead's Open Label Criticized
16 Companies Sign Up
Executive Summary
NIH's Collins brings together coalition after months of behind-the-scenes work. Meanwhile, Gilead's remdesivir trials are the center of huge expectation and controversy.
You may also be interested in...
Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Zydus Cadila Launches Third Salvo Against COVID-19 With Interferon
Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.
With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19
Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.